GlassScriptPhysician profile
Hieu Nguyen Tram
NPI 1003900366
$17,261.46
in general payments reported to CMS, 2019-2025
58 companies · $3,521 in 2025
The $3,521 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,213 · 2020: $1,768 · 2021: $2,704 · 2022: $1,508 · 2023: $1,770 · 2024: $2,778 · 2025: $3,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,013 · Education: $55.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,012.65 |
| Education | $55.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,207.51 | 2019-2025 | Linzess, Viberzi, Creon |
| Amgen INC. | $1,663.33 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,545.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $1,426.31 | 2019-2023 | |
| Lilly USA, LLC | $1,008.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $878.85 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $746.18 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $487.87 | 2019-2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $453.12 | 2021-2025 | |
| Pfizer INC. | $451.82 | 2019-2025 | |
| Astellas Pharma US INC | $435.50 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $384.40 | 2019-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $383.35 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $351.63 | 2023-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $346.49 | 2021-2023 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hieu Tram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.